GeNYC: Genomic Implementation Research in the Diverse Settings and Populations of New York City

GeNYC：纽约市不同环境和人群的基因组实施研究

• 批准号: 10822886
• 负责人: Carol R Horowitz
• 金额: $ 33.47万
• 依托单位: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-07-26 至 2024-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10822886
• 关键词: Administrative Supplement; COVID-19; Clinical; Clinical Trials; Data Analyses; Funding; Genomic medicine; Genomics; Genotype; Health; Healthcare; Hypertension; Manuscripts; Mental Depression; New York City; Pain management; Population; Population Heterogeneity; Pragmatic clinical trial; Publications; Randomized; Time; Writing; cost; demographics; genetic testing; implementation research; improved; patient population; prospective; recruit; timeline

Project Summary The promise of genomic medicine to transform healthcare and improve health will not be fully realized until discoveries become relevant to and available for use by diverse populations and their clinicians. As part of the IGNITE II network, we are implementing two prospective randomized pragmatic genotype-guided clinical trials (GUARDD-US and ADOPT-PGx) to determine the impact of implementing genetic testing on hypertension, depression, and pain therapies. This administrative supplement request is to extend the implementation timeline for these two pragmatic clinical trials by 24 month to allow for completion of: ADOPT PGx recruitment and study follow-ups, GUARDD-US follow-ups, data analysis, writing up of study results and closeout of all study activities.We expect the successful results from this clinical trial will provide critical evidence needed to drive the implementation of genomic medicine across broad demographics of patient populations.

项目摘要 基因组医学改变医疗保健和改善健康的承诺将无法完全实现 直到发现与不同人群及其临床医生相关并可供使用。 作为IGNITE II网络的一部分，我们正在实施两个前瞻性随机务实的 基因型指导的临床试验（GUARDD-US和ADOPT-PGx），以确定 对高血压、抑郁症和疼痛疗法进行基因检测。这一行政 补充要求是延长这两项实用临床试验的实施时间轴， 24个月以完成：ADOPT PGx招募和研究随访，GUARDD-US 随访、数据分析、撰写研究结果和结束所有研究活动。我们希望 这项临床试验的成功结果将为推动 在广泛的患者人群中实施基因组医学。